Tx360EU INTENDED USE
The Tx360EU Nasal Applicator device is intended to deliver fluids, selected by a healthcare professional, to the mucous membrane covering structures of the nasal pathway, such as the inferior turbinate, middle turbinate, superior turbinate, sphenopalatine foramen, nasal septum, etc. The Tx360EU provides an aid to physicians in the delivery of drugs used as nerve block agents when performing sphenopalatine ganglion nerve block for the purpose of treating headaches.
Dr. Tian Xia, is the sole owner of the company, had invented Tx360® device. It is currently available for sale in United States(Tx360®), and European Union Tx360EU).
Tian Medical is located in Libertyville, IL. The company is primarily engaged in venture funding, research and development of biotechnology and life sciences.
Tian Medical had developed the Tx360® and Tx360EU Nasal Applicator.
Tx360® / Tx360EU medical device is the one and only product of its kind commercially available for sale in United States(Tx360®) and European Union(Tx360EU) for use by medical professionals.
The Tx360EU Nasal Applicator was developed by a biotech research and development company in the United States. This medical device is currently being manufactured in Libertyville, Illinois, USA.
Tx360EU nasal applicator has a soft needle extension that allows the anesthetic agent to be delivered directly on to the sphenopalatine foramen. The result is instant headache relief, expected from a nerve block. The treatment takes less than 30 seconds, and most patients report pain reduction within a few minutes.
Because the SPG is located deep in the nasal cavity, a normal nasal spray cannot reach the desired location. Unlike other nasal sprays, the revolutionary, Tx360EU nasal applicator is designed to be gently inserted into a patient’s nose, as they sit, and deliver medication precisely and consistently to the area of the SPG.
The Tx360EU is not a headache treatment per se, it is a medication delivery device that transforms a SPGB into a quick, simple, comfortable procedure. As a result, practitioner can safely and efficiently perform the SPGNB as frequently as necessary for the purpose of restoring the normal physiologic function of the parasympathetic outflow in the cranial region – resolution of your headaches.
Warnings and Precautions
The Tx360EU Nasal Applicator should be used with care only by trained healthcare professionals. Complications may include:
Do not use the Tx360EU Nasal Applicator in the following conditions (contraindications):
Do not use the Tx360EU Nasal Applicator if:
Discard appropriately after use.
Reuse of the Tx360EU Nasal Applicator may cause serious infections and introduction of bacteria, such as VRE (Vancomycin-Resistant Enterococcus) or MRSA (Methicillin-Resistant Staphylococcus Aureus).
What is SPG Block (Sphenopalatine Ganglion Block) and why should I consider it for my patient?
The sphenopalatine ganglion block / sphenopalatine ganglion (SPG) is located just deep to the nasal mucosa posterior to the middle nasal turbinate. The SPG can be blocked by diffusion of local anesthetic through the overlying mucosa. Sensory, sympathetic and parasympathetic fibers pass through or synapse in the SPG, making it a key structure in various types of cephalgia. Temporarily blocking function of the SPG can provide prompt, and sometimes sustained, relief of pain. It is theorized that SPGB provides sustained relief by disrupting dysfunctional neuronal activity, allowing restoration of normal function.
Currently there is very little to offer the chronic migraine headache patient. Nearly two thirds of patients discontinue prescription medications due to inadequate relief and side-effects.
SPG blocks achieve neuromodulation of the sphenopalatine ganglion complex. This means that the time-tested efficacy of the procedure has been shown to have both immediate and sustained results. These effects are typically sustained by interrupting the chaotic signaling associated with migraine.
Although proven effective, few physicians offer the SPG block to patients because the traditional procedures are uncomfortable and dangerous for the patient and demanding for the care giver. Traditionally, the block is attempted by navigating a cotton tip applicator through the nasal passages and place it there for 30 minutes, or with a long needle through the side of the head. These approaches carry risks and sometimes require sedation.
Today, establishing an SPG block has never been easier. The patented Tx360EU offers the practitioner the ability to offer a first-line treatment in the chronic headache patient. Tx360EU delivers medication that can sustain pain relief in a ten to thirty seconds procedure that is comfortable and quick. With Tx360EU, SPG may be achieved without needles, cotton swabs, atomizer sprays or systemic narcotics.
SPG blocks have time-tested efficacy when it comes to serious chronic and episodic migrainous pain.
SPG Blocks have been performed for centuries, but new technology allows them to be performed with comfort and ease
Tx360EU is a single-use, disposable catheter that delivers medication through the nasal passages to a difficult-to-reach ganglion located at the back of the nose easily, safely, efficiently and accurately (only 0.6cc of medication needed).
When used as indicated, Tx360EU delivers the medication immediately proximate to the ganglion to achieve a Sphenopalatine Ganglion or SPG block. Interventional radiologists, neurologists, internists, emergency departments and pain specialists are interested in utilizing Tx360EU for a safe, comfortable and quick delivery of the medication required for the SPG block procedure.
The drug delivery innovation, Tx360EU, is drawing the attention of physicians who treat patients with chronic and episodic migraine, cluster headache, and chronic daily headache and for other applications. The SPG blocks have been studied for many disorders for over a century. More recently however, the block has been associated with profound neuromodulation of the SPG complex, resetting the chaotic signaling associated with chronic migraine with both immediate and sustained results.
Though widely accepted as effective, few physicians are willing to perform an SPG block because the traditional procedures are uncomfortable for the patient and demanding for the caregiver. Formerly, the block was attempted by navigating a cotton tip applicator through the nasal passages, by atomizing a spray or with a long needle through the side of the head. These older approaches carry risks, sometimes require sedation and may not be effective in all patients.
Headache alone affects nearly 45 million individuals, and migraine occurs in 6.8% of men and 15-18% of women. Nearly two-thirds of headache patients discontinue prescription medications due to inadequate relief and side effects. The SPG block may also have utility in the treatment of other disorders. Tx360EU is designed to deliver medicines right onto the sphenopalatine foreman in order to block the entire SPG apparatus. Tx360EU allows easy and accurate placement of medications right onto the sphenopalatine foramen, no imaging guidance is necessary.